Stay updated on Nivolumab in AML Remission at High Risk Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.

Latest updates to the Nivolumab in AML Remission at High Risk Clinical Trial page
- Check4 days agoChange DetectedAdministrative updates were added: a government funding notice and revision to v3.4.1 replacing v3.4.0, which do not affect core trial content or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check11 days agoChange DetectedThe updates are minor UI and metadata changes (Show glossary; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0) that do not alter the core study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedThe updates include adding a 'Locations' and 'Texas' label and removing the 'Texas Locations' header, and removing the HHS Vulnerability Disclosure footer link. These are minor labeling and navigation changes that do not affect study data, eligibility, or user actions.SummaryDifference0.2%

- Check68 days agoChange DetectedRevision notice updated from v3.3.1 to v3.3.2 across the page footer, indicating a minor site update that does not affect study content or usability. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedA new note clarifying that publications are automatically filled from PubMed and may not be about the study was added, and the footer revision label changed from v3.2.0 to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in AML Remission at High Risk Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Remission at High Risk Clinical Trial page.